| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, s...
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of...
Further details will be provided in an official letter from FDA within 30 days and the company plans to address their questions...
The RESTORE-FA trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of IV a...
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of...
https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics
esign Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative g...
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology co...
